Synovial Sarcoma Foundation

27/08/2026

One of the biggest barriers to making T cell therapies available to more patients is not the science. It is the manufacturing.

A new study out of Hiroshima University presents a method for producing engineered T cells targeting NY-ESO-1, one of the most clinically validated targets in synovial sarcoma, at clinical scale, more precisely, without viral vectors, and potentially at lower cost than current methods allow.

It is early stage research. But it addresses a real and practical bottleneck in getting the next wave of synovial sarcoma therapies from the lab to the patient.

Read the full article: https://synovialsarcoma.org/how-better-t-cell-manufacturing-could-unlock-the-next-wave-of-synovial-sarcoma-therapies/

A study published in Cytotherapy by Kayo Toishigawa, Kenta Magoori, Hiroyuki Sato, and colleagues at Hiroshima University, in collaboration with Repertoire

26/08/2026

The SSF Registry and Biorepository is open to every patient and family touched by synovial sarcoma.

- Newly diagnosed: Start here.
- Long-term survivors: Your data is the rarest we can collect.
- Bereaved families: Their tumor can still teach us.
- Pediatric families: Your child's biology is uniquely underrepresented.

22/08/2026

🏁 National Surgical Oncologist Day! 🏁

Today, we’re celebrating the incredible surgeons who have helped so many in the synovial sarcoma community through complex surgeries, recurrences, and life-changing moments.

Thank you for your skill, dedication, compassion, and for helping give our community more time. 💙

We’re grateful for every surgical all-star who has been part of a patient’s journey. 🏆

21/08/2026

Merck and Moderna are making headlines with their personalized mRNA cancer vaccine breakthrough in melanoma.

For the synovial sarcoma community, this news is especially meaningful because researchers are exploring the same approach for synovial sarcoma.

The Synovial Sarcoma Foundation is working directly with researchers who have the science and development in place to advance a personalized mRNA vaccine for synovial sarcoma. What’s needed now is the funding to move this research forward and, ultimately, bring this potential treatment to patients.

For a rare and aggressive cancer, this could represent a whole new approach to treatment.

Help us bring the next breakthrough to synovial sarcoma.

Read the full article here: https://synovialsarcoma.org/why-a-melanoma-vaccine-breakthrough-matters-for-synovial-sarcoma/

Support the research: https://synovialsarcoma.org/donate/

Merck and Moderna are making headlines after their personalized mRNA cancer vaccine entered Phase 3 clinical trials for melanoma. For most people, it is an

19/08/2026

National Patient Advocacy Day!

Don’t be afraid to speak up. Ask questions. Seek second opinions. Share your story. Join research. Raise awareness.

Advocate for yourself.
Advocate for others.
Advocate for our community.

Every question you ask, every story you share, and every action you take can help move us closer to better treatments and better outcomes.

Your voice can create change. Use it.

18/08/2026

📢 Reminder: The next International Synovial Sarcoma Tumor Board is coming up!

🌍 This unique global resource brings together specialists from around the world, because no patient should have to face a rare diagnosis without access to expert collaboration.

To join the Tumor Board or refer a case, please email [email protected]

📅 Friday, August 21
⏰ 1 PM ET

Together, we are building a future where every synovial sarcoma patient has access to the expertise they deserve.

17/08/2026

New preclinical research from Japan may offer treatment options for synovial sarcoma patients currently ineligible for TECELRA due to HLA matching requirements.

Scientists have developed a CAR-T cell approach that does not require HLA matching, meaning it could one day be available to patients that current therapies cannot reach.

Read the full article here: https://synovialsarcoma.org/a-new-car-t-cell-approach-for-synovial-sarcoma-that-does-not-require-hla-matching/

A new preclinical study published in Biomedicine and Pharmacotherapy by Tomohiro Miyazaki, Yudai Murayama, Naoki Oike, and colleagues from the Department of

17/08/2026

Today is National Nonprofit Day - a day to celebrate the organizations working every day to create change. 💙

We’re proud to be more than just a nonprofit. We are a research-driven organization where 100% of donated funds go directly toward advancing research, clinical resources, and better treatment options for the synovial sarcoma community.

Yes, you read that right. Every donation helps move the science forward, funding the discoveries, collaborations, and programs needed to change the future of this disease.

Rare diseases need dedicated advocates, and because of supporters like you, progress is happening.

If you’d like to help accelerate research and bring hope to patients and families, consider making a donation today. Every contribution makes a difference. 💙

Support our mission here: https://synovialsarcoma.org/donate

13/08/2026

Biomarker testing should be standard of care for every synovial sarcoma patient.

But right now, it isn't.

That means we have to keep advocating for ourselves.

Ask the question.
Start the conversation.
Request biomarker testing.
Fight for the care you deserve.

The right test can open the door to treatment options, clinical trials, and more informed decisions about your care.

Your voice matters. Advocacy starts with asking.

11/08/2026

Kaela was working as an oncology nurse when she was diagnosed with synovial sarcoma at 28. Six years, multiple relapses, and one groundbreaking treatment later, she is here, and she has a lot to say.

We sat down with Kaela to talk about what her journey actually looked like, what it took to access Tecelra as an international patient, and why she chose to donate her tumor to the Synovial Sarcoma Registry and Biorepository.

Her story is not just one of survival. It is a case for why research funding, patient participation, and advocacy are not optional in this disease.

Tap below to read the full conversation. And if you are eligible, join Kaela in the registry.

https://synovialsarcoma.org/in-conversation-with-kaela-how-research-gave-a-mom-of-two-a-second-chance-at-life/

Kaela Graham-Bowman's story reached national audiences this year when she was featured on 60 Minutes Australia. An Afghanistan veteran and nurse, Kaela was